Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. - Wikidata - awgldk - TriplyDB

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

http://www.wikidata.org/entity/Q42067834

about

Here, There, and Everywhere: The Ubiquitous Distribution of the Immunosignaling Molecule Lysophosphatidylcholine and Its Role on Chagas Disease Structural Basis of Molecular Recognition of the Leishmania Small Hydrophilic Endoplasmic Reticulum-associated Protein (SHERP) at Membrane Surfaces Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure Metabolomics to unveil and understand phenotypic diversity between pathogen populations CYP5122A1, a novel cytochrome P450 is essential for survival of Leishmania donovani Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms Drug resistance in eukaryotic microorganisms.In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.A Computational Methodology to Overcome the Challenges Associated With the Search for Specific Enzyme Targets to Develop Drugs Against Leishmania major.Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues.Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1.Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.Leishmania promastigotes lack phosphatidylserine but bind annexin V upon permeabilization or miltefosine treatment.Characterization of Leishmania major phosphatidylethanolamine methyltransferases LmjPEM1 and LmjPEM2 and their inhibition by choline analogs Structures, targets and recent approaches in anti-leishmanial drug discovery and development.Dynamics of sterol synthesis during development of Leishmania spp. parasites to their virulent form.Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania.Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletion Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone.Treatment of leishmaniasis with miltefosine: 2008 status.Lipid synthesis in protozoan parasites: a comparison between kinetoplastids and apicomplexans Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism.Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids.Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery.Drug delivery systems for the topical treatment of cutaneous leishmaniasis.Leishmania cell wall as a potent target for antiparasitic drugs. A focus on the glycoconjugates.Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania.Chemotherapy of leishmaniasis: present challenges.Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance.Hexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells.Changes in Lipid and Fatty Acid Composition During Intramacrophagic Transformation of Leishmania donovani Complex Promastigotes into Amastigotes.Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.Lipidomics and anti-trypanosomatid chemotherapy.In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.Phospholipases a in trypanosomatids.

P2860

Q26765838-EA07C498-91D7-4B96-BCDD-1D7338F70732 Q27666058-07725AB2-CDBB-4A64-B61C-0978A27147D5 Q28271849-37C99D1C-B3F8-490C-A1E7-DF6D6AC7BF57 Q28306178-DA58DFD1-B102-488B-8EED-3D4888EBD58D Q28476399-20CB52C7-E670-4B86-AB93-A5B07260F7F0 Q28477209-C654C2CA-5D15-4B8E-893D-2F05FAA7471C Q28480626-42943832-94CF-4792-8191-2A5016B57AFB Q28492881-8763C0EE-655D-4B73-BE00-CCFCAC978BD7 Q28554770-B5B18B2A-FCD0-49A5-B74F-2A0613EC07A0 Q30248243-4CA96B0E-5656-4B79-92A7-3D068BFDAE7B Q30380900-6FB3DB94-69E6-4522-AA5F-03A60F427D7E Q33797941-93A98C55-BDA8-40DC-89FB-EE0B96C6915E Q33870440-418C2388-BC1F-4725-A9F2-72B7DAF3B9A3 Q34058013-CAC78983-413A-4026-862B-A1E220096BEF Q34069469-EEB711B7-9E1E-4DF5-9F67-D4230A5C0E0A Q34369251-7004E9F2-F243-44E6-A5D2-A7D94C1B4F66 Q34616125-B12EF42F-688D-4596-BA1E-A4DB7EA9774F Q35012968-407E683C-370E-4FB3-89FF-200AF9D0BE47 Q36793673-112D1421-E54B-469C-9870-6E1A2B278C3C Q36957213-2250C798-5790-4C0D-B6CF-3B77FA64DB08 Q36970766-CC7A2554-8BE8-4735-A388-602EC5D8267D Q37092398-443F2532-2078-4162-9057-3A16B382E544 Q37249719-4E3CBE61-3B01-4E59-BF1D-AEA56129906B Q37315680-A4EBBBA5-2208-415B-BEE1-B18F6B1162FA Q37450724-00F7B61C-9B60-4F92-B100-D554FC059621 Q37613357-91C067A6-9B3F-460B-BBF8-3B951D06AA65 Q37718965-D4439240-6220-4328-A31F-884FA270CDC3 Q37763950-C1F8193B-3102-4A41-B244-90F021205C14 Q38020882-81C82499-B164-4A01-9230-EE643F2AA875 Q38541158-BA15D4CB-7C67-4B3D-9C48-E497E815250D Q38626366-910AF0BC-F05E-4A06-9752-706A4B5561CE Q39011875-D5B3E01A-F19E-4D81-8D57-2FE1EEE94E60 Q39226324-68CA00D9-61A0-44C4-AD92-ABB85A620CE4 Q39560646-9EF8540C-79EE-4F83-BF5B-34ED696F1780 Q40007234-0905E7E6-D5FB-423C-BBC8-30B88340E3DE Q40345051-0BF23C00-1C91-431C-9BFE-21054645BD76 Q40802236-5B23E16E-DF11-48E7-B2DF-16AF8B4FD45F Q41203049-DA26EC4F-54CB-4AC6-984B-54711373E244 Q41844113-AEFD829B-58FA-4D14-A608-4BA011BC9625 Q42716413-BB88D6D6-4340-4B5B-9959-64AD0CBF2EED

P2860

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

http://www.wikidata.org/entity/Q42067834

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

@en

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

@nl

type

label

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

@en

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

@nl

prefLabel

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

@en

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

@nl

P1433

Q42067834-642BC79E-7503-4710-95AF-ADA5D3C49095

P1476

Q42067834-D73A7B42-1EE5-4B43-A243-DD375B0E35BA

P2093

Q42067834-47872376-997E-4E6F-9A68-5237D46C25D6

Q42067834-59174B63-545F-48DD-B32D-1F86B76A0107

Q42067834-AF0E3821-0969-400D-9611-1B29A2F413C6

Q42067834-C8673BCF-52CB-4A9F-956A-B1E12E2D0DDC

Q42067834-DB87187B-B033-4F9A-9915-8E0018F355CB

P2860

Q42067834-07C0040D-9CE7-4242-88FD-14027BCB0948

Q42067834-0C7387DB-43E7-43DE-A6F7-AFE0DCADDDB8

Q42067834-1E1543DA-7200-4465-AD80-FC2FBCC5B59F

Q42067834-25D50B78-DF91-41B9-A8B8-49BD67663937

Q42067834-2A8621BB-A10D-4DAC-9228-98440CD7BBCD

Q42067834-2B6CD418-5837-4CD7-AB74-E398A7C236AC

Q42067834-347546CC-FB2D-4583-B7D9-1C12712EDC29

Q42067834-35C3F3B9-3FBF-4402-BF7F-D0213C4A42C1

Q42067834-3F72A765-5DFB-4EF2-A3B3-AAE4836B9912

Q42067834-3FCFB82F-2454-45CF-9909-070836F1C20C

P304

Q42067834-28337CE2-73F1-4E3B-92DC-EF97BF5870E3

P31

Q42067834-7EF88261-B72F-43C3-BD36-3EB21BEA6736

P356

Q42067834-49D35E29-4110-446B-B6C9-A0DA41D5FE1D

P407

Q42067834-46F57C65-CE2A-4AAB-A063-227E61ABFE88

P433

Q42067834-EA29311B-81BA-4B3C-87FD-1AF331BB3582

P478

Q42067834-94F245D8-C50A-4E4B-91F9-E5DFA47B3BB9

P577

Q42067834-133DA40D-0486-49DD-B375-FD8B0872D871

P5875

Q42067834-D7E4DBBA-3A36-4139-A3F8-9D049B1F5543

P698

Q42067834-5021CD31-C778-469F-B26C-9FCB42B926D8

P932

Q42067834-3EAFECF6-7931-4D4E-8D85-3DBB37F89DAC

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

@en

P2093

K Gaudin

http://www.w3.org/2001/XMLSchema#string

M Rakotomanga

http://www.w3.org/2001/XMLSchema#string

P Chaminade

http://www.w3.org/2001/XMLSchema#string

P M Loiseau

http://www.w3.org/2001/XMLSchema#string

S Blanc

http://www.w3.org/2001/XMLSchema#string

P2860

Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients

Mechanism of amphotericin B resistance in Leishmania donovani promastigotes.

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.

Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.

Chemotherapy of leishmaniasis.

Current scenario of drug development for leishmaniasis.

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.

Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.

Hexadecylphosphocholine inhibits phosphatidylcholine synthesis via both the methylation of phosphatidylethanolamine and CDP-choline pathways in HepG2 cells.

P304

1425-1430

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01123-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6561229

http://www.w3.org/2001/XMLSchema#string

P698

17242145

http://www.w3.org/2001/XMLSchema#string

P932

1855451

http://www.w3.org/2001/XMLSchema#string